CVS Health price target lowered to $79 from $82 at Barclays

Barclays analyst Andrew Mok lowered the firm’s price target on CVS Health (CVS) to $79 from $82 and keeps an Overweight rating on the shares. Following Q1 earnings and “several negative data points” around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.